Topline data were announced from a phase 3 trial evaluating somapacitan in children born small for gestational age, with Noonan syndrome, or with idiopathic short stature.

N) today presented data from the Phase III REAL8 basket study, which showed that once-weekly Sogroya (somapacitan) was ...

Results from the Phase III REAL8 basket study found that once-weekly Sogroya was effective in children with growth disorders, including those born small for gestational age, with Noonan syndrome, or ...

evaluated the efficacy and safety of somapacitin in children aged 2 to 10 years born small for gestational age (SGA), or with Turner Syndrome (TS), Noonan syndrome (NS), or idiopathic short ...

The Danish pharmaceutical giant said the drug was more effective than a daily growth hormone in children with Noonan syndrome--a genetic condition that stops typical development in some parts of ...

The Danish pharmaceutical giant said the drug was more effective than a daily growth hormone in children with Noonan syndrome--a genetic condition that stops typical development in some parts of the ...

In Noonan syndrome, Sogroya achieved 10.4 cm/year height gain vs 9.2 cm/year with daily somatropin. Don’t miss this list of 3 high-yield stocks—including one delivering over 10%—built for ...

INVER GROVE HEIGHTS, Minn. — Two mothers are finding strength in each other as they fight for a possible groundbreaking ...

Dion's recent Eurovision appearance has renewed focus on her diagnosis of Stiff Person Syndrome, a rare neurological ...

Meanwhile, Sogroya demonstrated superiority over Novo’s daily growth hormone in children with Noonan syndrome (NS) and in children born small for gestational age (SGA) when compared to a lower ...